Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan +/- Adebrelimab in HER2-Expressing la/mUC
NCT07241793Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in urothelial carcinoma (UC), sponsored by Sun Yat-sen University. Started Nov 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07241793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241793.